How to buy I-Mab (IMAB) stock

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 228 staff and has a trailing 12-month revenue of around 0.00.

I-Mab stock price (NASDAQ: IMAB)

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$81.07
52-week range	$28.29 - $85.40
50-day moving average	$76.68
200-day moving average	$61.94
Wall St. target price	$89.73
PE ratio	73.4873
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.06

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of I-Mab by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab price performance over time

Historical closes compared with the close of $81.07 from 2021-05-28

1 week (2021-07-13)	N/A
1 month (2021-06-24)	-0.26%
3 months (2021-04-20)	N/A
6 months (2021-01-20)	N/A

1 year (2020-07-20)	N/A
2 years (2019-07-20)	N/A
3 years (2018-07-20)	N/A
5 years (2016-07-20)	N/A

Is I-Mab under- or over-valued?

Valuing I-Mab stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of I-Mab's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

I-Mab's P/E ratio

I-Mab's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 73x. In other words, I-Mab shares trade at around 73x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

I-Mab's EBITDA

I-Mab's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $168.3 million.

The EBITDA is a measure of a I-Mab's overall financial performance and is widely used to measure a its profitability.

I-Mab financials

Revenue TTM	$1.5 billion
Operating margin TTM	10.08%
Gross profit TTM	$1.5 billion
Return on assets TTM	2.41%
Return on equity TTM	14.06%
Profit margin	30.53%
Book value	$78.49
Market capitalisation	$6 billion

TTM: trailing 12 months

Shorting I-Mab shares

There are currently 2.1 million I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 0.7% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.

I-Mab's "short interest ratio" (SIR)

I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 514127.57793765). I-Mab's SIR currently stands at 4.17. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 4170 shares are currently held short.

However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 30 shares are currently held short) or 0.0704% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 70 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.

Find out more about how you can short I-Mab stock.

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. .

Frequently asked questions

What percentage of I-Mab is owned by insiders or institutions?
Currently 0.841% of I-Mab shares are held by insiders and 38.336% by institutions. How many people work for I-Mab?
Latest data suggests 228 work at I-Mab. When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December. Where is I-Mab based?
I-Mab's address is: West Tower, OmniVision, Shanghai, China, 201210 What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030 What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103